Skip to main content

Coordinated regulation using small-molecule drugs enables controlled therapeutic genome editing and enhanced genomic precision in situ.

Zhang J, Chen L, Zhu X, Cai Y, Wei S, Zhou X, Shi Y, Liu C, Huang C, Bi S, Wu F, Zhou X, Hong J, Wang Y
Sci Transl Med. 2026 May 27;18(851):eadx7857. doi: 10.1126/scitranslmed.adx7857. Epub 2026 May 27. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

ID Plasmid Purpose
250956PRINCE-SpCas9-2PRINCE drug inducible gene editing system based on SpCas9 (Lentiviral-Part II: the sgRNA expression is under drug-mediated control)
250957PRINCE-SaCas9-1PRINCE drug inducible gene editing system based on SaCas9 (AAV-Part I : the expression of SaCas9-NES)
250958PRINCE-SaCas9-2PRINCE drug inducible gene editing system based on SaCas9 (AAV-Part II : the expression of 2x ERT2 and the sgRNA is under drug-mediated control)
251232Little Prince-enOsCas12f1Drug inducible gene editing system based on enOsCas12f1 (Little Prince)
251233Little Prince (TnpB)Drug inducible gene editing system based on TnpB (Little Prince)
251234Little Prince (enIscB)Drug inducible gene editing system based on enIscB (Little Prince)
251235PRINCE-SpCas9-1PRINCE drug inducible gene editing system based on SpCas9 (Lentiviral-Part II: the SpCas9 expression is under drug-mediated control)

Antibodies from Article